

FIG. 1




FIG. 2

Changes in contrast-enhancing lesions:




FIG. 3





FIG. 4B

FIG. 4A






FIG. 6B

FIG. 6A

Trough levels of Zenapax in the current dosing regimen
 (1mg/kg max 100mg) completely saturate CD25 receptor on
 peripheral T cells:





FIG. 7

Parallel to complete blockage of CD25 by Zenapax, also the proliferation of in-vivo
 activated T cells to IL-2 decreases



Upregulation of CTLA-4 on CD4+ T cells during administration of Zenapax:

Susan Alpert Siegel, Ph.D.
Klarquist Sparkman, LLP
121 SW Salmon Street, Suite 1600
Portland, Oregon 97204
Telephone: (503) 226-7391
Express Mail Label No. EV339203197US
Date of Deposit: June 27, 2003

Our Ref. No. 4239-66190
First Named Inventor: Roland Martin
For: METHOD FOR THE TREATMENT
OF MULTIPLE SCLEROSIS

Sheet 9 of 9




FIG. 9